{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T05:59:47Z","timestamp":1780898387282,"version":"3.54.1"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Retinopathy of prematurity (ROP) is a vasoproliferative retinal disorder in preterm infants driven by impaired vascular development, hypoxia, oxidative stress, and pathological angiogenesis. Current treatments mainly target VEGF signaling but do not directly address upstream oxidative injury. Hepcidin, a key iron-homeostasis regulator, may modulate redox balance and angiogenic activation. However, whether hepcidin is reduced in ROP and whether supplementation mitigates hypoxia-induced oxidative stress and abnormal angiogenesis in retinal endothelial cells remain unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate the effects of hepcidin on human retinal microvascular endothelial cells (hRMECs) under oxidative stress and assess its translational potential in ROP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Clinical data were collected from 35 preterm infants with gestational age &amp;lt;36 weeks, including 24 non-ROP controls and 11 ROP infants. Gestational age, birth weight, ROP stage, and serum hepcidin were analyzed. hRMECs were exposed to 1% O\n                      <jats:sub>2<\/jats:sub>\n                      to establish a hypoxia model. Cell viability, VEGFA and HIF-1\u03b1 mRNA expression, secreted VEGFA, intracellular reactive oxygen species (ROS), transcriptomic changes, and tube formation were evaluated. Hepcidin was added under hypoxia to assess its effects on oxidative stress and angiogenic activation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Infants with ROP had lower gestational age and birth weight than controls, and gestational age differed across ROP stage groups. Serum hepcidin-related signals were numerically lower in ROP infants, but no significant stage-dependent decrease was observed. In hRMECs, 1% O\n                      <jats:sub>2<\/jats:sub>\n                      altered cell viability, upregulated VEGFA and HIF-1\u03b1 mRNA, increased secreted VEGFA, and promoted ROS accumulation, confirming a hypoxia-induced endothelial stress model. Transcriptomic analysis suggested that hepcidin affected hypoxia-responsive metabolic pathways, including cysteine and methionine, selenocompound, and tryptophan metabolism. Functional validation showed that hepcidin reduced VEGFA at transcript and secreted protein levels, decreased intracellular ROS, and suppressed hypoxia-induced tube formation by reducing junction points, branch points, and total tube length.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      This study provides preliminary clinical and experimental evidence supporting a potential role of hepcidin-related signaling in ROP. Although the clinical findings are exploratory, the\n                      <jats:italic>in vitro<\/jats:italic>\n                      results indicate that hepcidin can attenuate hypoxia-induced oxidative stress and pathological angiogenic activation in retinal endothelial cells. Hepcidin may represent a biologically relevant pathway and potential candidate for further biomarker and therapeutic research in ROP.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fped.2026.1821139","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T05:33:52Z","timestamp":1780896832000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Serum hepcidin is associated with retinopathy of prematurity and modulates oxidative stress and angiogenic responses in retinal microvascular endothelial cells"],"prefix":"10.3389","volume":"14","author":[{"given":"Hui","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Neonatology, Shenzhen Children's Hospital","place":["Shenzhen, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiyun","family":"Chen","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Sciences (Shenzhen), Sun Yat-sen University","place":["Shenzhen, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Cheng","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Sciences (Shenzhen), Sun Yat-sen University","place":["Shenzhen, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingbo","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Neonatology, Shenzhen Children's Hospital","place":["Shenzhen, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e2021053924","DOI":"10.1542\/peds.2021-053924","article-title":"Retinopathy of prematurity: a global perspective and recent developments","volume":"150","author":"Sabri","year":"2022","journal-title":"Pediatrics"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13052-021-00991-z","article-title":"Using ROPScore and CHOP ROP for early prediction of retinopathy of prematurity in a Chinese population","volume":"47","author":"Sun","year":"2021","journal-title":"Ital J Pediatr"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e35260","DOI":"10.7759\/cureus.35260","article-title":"Challenge accepted: retinopathy of prematurity (ROP) during COVID-19","volume":"15","author":"Sahu","year":"2023","journal-title":"Cureus"},{"key":"B4","doi-asserted-by":"publisher","first-page":"101018","DOI":"10.1016\/j.preteyeres.2021.101018","article-title":"Assessment and management of retinopathy of prematurity in the era of anti-vascular endothelial growth factor (VEGF)","volume":"88","author":"Tsai","year":"2022","journal-title":"Prog Retin Eye Res"},{"key":"B5","doi-asserted-by":"publisher","first-page":"8461","DOI":"10.3390\/ijms25158461","article-title":"Natural products in the treatment of retinopathy of prematurity: exploring therapeutic potentials","volume":"25","author":"Heo","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B6","doi-asserted-by":"publisher","first-page":"3022","DOI":"10.1172\/JCI42142","article-title":"Retinopathy of prematurity: understanding ischemic retinal vasculopathies at an extreme of life","volume":"120","author":"Sapieha","year":"2010","journal-title":"J Clin Invest"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0039-6257(88)90068-9","article-title":"Retinopathy of prematurity","volume":"33","author":"Sira","year":"1988","journal-title":"Surv Ophthalmol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.survophthal.2022.11.007","article-title":"Retinopathy of prematurity: a review of pathophysiology and signaling pathways","volume":"68","author":"Fevereiro-Martins","year":"2023","journal-title":"Surv Ophthalmol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1016\/j.ophtha.2020.12.028","article-title":"Retinal detachment after treatment of retinopathy of prematurity with laser versus intravitreal anti-vascular endothelial growth factor","volume":"128","author":"Barry","year":"2021","journal-title":"Ophthalmology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1097\/IAE.0000000000002663","article-title":"Rates and risk factors for recurrence of retinopathy of prematurity after laser or intravitreal anti-vascular endothelial growth factor monotherapy","volume":"40","author":"Ling","year":"2020","journal-title":"Retina Phila Pa"},{"key":"B11","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1111\/dmcn.15468","article-title":"Retinopathy of prematurity","volume":"65","author":"Dammann","year":"2023","journal-title":"Dev Med Child Neurol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"6493","DOI":"10.3390\/ijms22126493","article-title":"Hepcidin-ferroportin interaction controls systemic iron homeostasis","volume":"22","author":"Nemeth","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B13","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41586-020-2668-z","article-title":"Structure of hepcidin-bound ferroportin reveals iron homeostatic mechanisms","volume":"586","author":"Billesb\u00f8lle","year":"2020","journal-title":"Nature"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41420-020-00346-3","article-title":"Hepcidin overexpression in astrocytes alters brain iron metabolism and protects against amyloid-\u03b2 induced brain damage in mice","volume":"6","author":"Zhang","year":"2020","journal-title":"Cell Death Discov"},{"key":"B15","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/s41419-018-0568-z","article-title":"Endogenous hepcidin synthesis protects the distal nephron against hemin and hemoglobin mediated necroptosis","volume":"9","author":"van Swelm","year":"2018","journal-title":"Cell Death Dis"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1167\/iovs.18-25525","article-title":"Discovering mechanisms in the changing and diverse pathology of retinopathy of prematurity: the weisenfeld award lecture","volume":"60","author":"Hartnett","year":"2019","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B17","doi-asserted-by":"publisher","first-page":"458","DOI":"10.20471\/acc.2018.57.03.08","article-title":"Pro-oxidants and antioxidants in retinopathy of prematurity","volume":"57","author":"Banjac","year":"2018","journal-title":"Acta Clin Croat"},{"key":"B18","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s10456-007-9066-0","article-title":"Retinopathy of prematurity","volume":"10","author":"Chen","year":"2007","journal-title":"Angiogenesis"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1016\/S0140-6736(13)60178-6","article-title":"Retinopathy of prematurity","volume":"382","author":"Hellstr\u00f6m","year":"2013","journal-title":"Lancet"},{"key":"B20","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3760\/cma.j.issn.2095-0160.2017.01.006","article-title":"Relationship of human microvascular endothelial cell activation and adenosine level under the hypoxia","volume":"35","author":"Ai","year":"2017","journal-title":"Chin J Exp Ophthalmol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e80550","DOI":"10.7554\/eLife.80550","article-title":"Retinopathy of prematurity: metabolic risk factors","volume":"11","author":"Fu","year":"2022","journal-title":"eLife"},{"key":"B22","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.mad.2017.11.003","article-title":"Effects of different hypoxia degrees on endothelial cell cultures\u2014time course study","volume":"172","author":"Baldea","year":"2018","journal-title":"Mech Ageing Dev"},{"key":"B23","doi-asserted-by":"publisher","first-page":"847611","DOI":"10.3389\/fendo.2022.847611","article-title":"Kynurenic acid acts as a signaling molecule regulating energy expenditure and is closely associated with metabolic diseases","volume":"13","author":"Zhen","year":"2022","journal-title":"Front Endocrinol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"501","DOI":"10.3324\/haematol.2009.014399","article-title":"Hepcidin targets ferroportin for degradation in hepatocytes","volume":"95","author":"Ramey","year":"2010","journal-title":"Haematologica"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1821139\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T05:33:54Z","timestamp":1780896834000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1821139\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":24,"alternative-id":["10.3389\/fped.2026.1821139"],"URL":"https:\/\/doi.org\/10.3389\/fped.2026.1821139","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]},"article-number":"1821139"}}